<DOC>
	<DOC>NCT01930175</DOC>
	<brief_summary>To evaluate the safety, tolerability and efficacy of a single intravneous infusion of VAY736, compared to placebo, in pemphigus vulgaris patients.</brief_summary>
	<brief_title>Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Pemphigus</mesh_term>
	<criteria>Adult patients 20 to 70 years of age Confirmed diagnosis of pemphigus vulgaris Presence of mild to moderate pemphigus vulgaris Patients must weight between 40 kg and 150 kg inclusive on a stable dose of oral corticosteriod therapy (with or without azathioprine or mycophenolate) Pregnant or nursing (lactating) women Women of childbearing potential unless they are using a highly effective method of birth control during dosing and for 4 months following study treatment Recent previous treatment with photo therapy, biological therapy, steroids, immunosuppresive agents (unless washout period applied) Active or recent history of clinically significant infection use of rituximab within 1 year Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Pemphigus vulgaris</keyword>
	<keyword>pemphigus</keyword>
	<keyword>blistering disease</keyword>
</DOC>